Heron Therapeutics' APONVIE Included in Newly Released PONV Guidelines

Heron Therapeutics' APONVIE, an aprepitant injectable emulsion, has been included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. The guidelines recognize APONVIE as a long-acting, quick-onset NK-1 antagonist for PONV prevention in adults and note its effectiveness in reducing PONV risk. The guidelines also emphasize the importance of long-acting antiemetic strategies to protect against post-discharge nausea and vomiting.